Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001

By | June 14, 2021
Enterprise Therapeutics Ltd today announced it has successfully dosed the first subjects in a Phase 1 trial for its novel inhaled cystic fibrosis therapy, ETD001.